Success Metrics

Clinical Success Rate

50.0%

Based on 1 completed trials

Completion Rate

50%(1/2)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(33%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(1)

Other(1)

Detailed Status

Completed1

Terminated1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed133%

terminated133%

unknown133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_1

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

NCT02957032

unknownphase_1

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

NCT05468294

completedphase_1

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03207191

Clinical Trials (3)

Showing 3 of 3 trials

NCT02957032Phase 1

A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Terminated

NCT05468294Phase 1

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

Unknown

NCT03207191Phase 1

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3